Literature DB >> 10926191

Cavernous transformation of the portal vein secondary to tumor thrombosis of hepatocellular carcinoma: spiral CT visualization of the collateral vessels.

B Song1, P Min, M Oudkerk, X Zhou, Y Ge, J Xu, W Chen, X Chen.   

Abstract

BACKGROUND: We investigated the constituting collateral vessels in cavernous transformation of the portal vein (CTPV) caused by tumor thrombosis of hepatocellular carcinoma (HCC) by using contrast-enhanced spiral computed tomographic (CT) examination.
METHODS: Fifty-four histopathologically proven HCC patients with tumor thrombosis-induced CTPV were retrospectively included and assigned to cirrhosis negative (n = 31) and positive (n = 23) groups. Another 15 cirrhotic patients with portal hypertension but no HCC and CTPV were used for comparison. Standardized dual-phase contrast-enhanced spiral CT was performed for all patients. CT appearances of the collateral vessels of CTPV were observed, and their visualization rates were analyzed.
RESULTS: Biliary (cystic and paracholedochal veins) and gastric (left and right gastric veins) branches of the portal vein were the most frequently visualized collateral vessels of CTPV. There was a marked difference in CT visualization rates for biliary branches between patients with and without CTPV (83-94% vs. 0). No difference existed in visualization rates for gastric branches across the three groups (77-87% for left gastric, 58-61% for right gastric vein).
CONCLUSIONS: Biliary and gastric branches of the portal vein are the major collateral vessels of CTPV. The intergroup differences in CT visualization rates may provide clues to the roles that they might play in the hemodynamic adaptation process of CTPV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926191     DOI: 10.1007/s002610000057

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  4 in total

1.  Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients.

Authors:  Xingshun Qi; Guohong Han; Zhanxin Yin; Chuangye He; Jianhong Wang; Wengang Guo; Jing Niu; Wei Zhang; Ming Bai; Daiming Fan
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

2.  Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.

Authors:  Yingqiang Zhang; Wenzhe Fan; Yu Wang; Ligong Lu; Sirui Fu; Jianyong Yang; Yonghui Huang; Wang Yao; Jiaping Li
Journal:  Oncologist       Date:  2015-10-07

3.  Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports.

Authors:  Satoshi Komiyama; Kazushi Numata; Satoshi Moriya; Hiroyuki Fukuda; Makoto Chuma; Shin Maeda
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

4.  Transhepatic Embolization of Congenital Intrahepatic Portosystemic Venous Shunts with Associated Aneurysms.

Authors:  Kalyan Paudel; Eric K Hoffer
Journal:  Case Rep Med       Date:  2015-07-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.